CN118027175B - 冻存prp与干细胞外泌体治疗无菌性炎症疾病 - Google Patents
冻存prp与干细胞外泌体治疗无菌性炎症疾病 Download PDFInfo
- Publication number
- CN118027175B CN118027175B CN202410230477.2A CN202410230477A CN118027175B CN 118027175 B CN118027175 B CN 118027175B CN 202410230477 A CN202410230477 A CN 202410230477A CN 118027175 B CN118027175 B CN 118027175B
- Authority
- CN
- China
- Prior art keywords
- prp
- active peptide
- stem cell
- cell exosomes
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 24
- 210000000130 stem cell Anatomy 0.000 title abstract description 9
- 208000027866 inflammatory disease Diseases 0.000 title abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 40
- 210000001612 chondrocyte Anatomy 0.000 claims abstract description 24
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 20
- 230000035755 proliferation Effects 0.000 claims abstract description 19
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000011282 treatment Methods 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 13
- 206010003246 arthritis Diseases 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 150000001413 amino acids Chemical group 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 14
- 210000000845 cartilage Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000000629 knee joint Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 210000003056 antler Anatomy 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- -1 aromatic amino acids Chemical class 0.000 description 6
- 210000002303 tibia Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000001188 articular cartilage Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 235000014705 isoleucine Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000005772 leucine Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 210000004417 patella Anatomy 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000005065 subchondral bone plate Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000008521 threonine Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000002374 tyrosine Nutrition 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- GOJCZVPJCKEBQV-UHFFFAOYSA-N Butyl phthalyl butylglycolate Chemical compound CCCCOC(=O)COC(=O)C1=CC=CC=C1C(=O)OCCCC GOJCZVPJCKEBQV-UHFFFAOYSA-N 0.000 description 1
- 101100328886 Caenorhabditis elegans col-2 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000283007 Cervus nippon Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 208000004367 Tibial Fractures Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000487 effect on differentiation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及冻存prp与干细胞外泌体治疗无菌性炎症疾病。具体的，采用冻存prp与干细胞外泌体治疗关节炎。本发明的prp和外泌体能够较好的促进骨关节炎软骨细胞增殖。将prp和外泌体以及本发明筛选的活性肽一起使用能够有效的治疗骨关节炎模型小鼠的关节炎症状，能够显著的降低关节炎相关基因的表达量，具有较好的治疗效果。
Description
技术领域
本申请涉及生物领域，具体的涉及冻存prp与干细胞外泌体治疗无菌性炎症疾病。
背景技术
“无菌性炎症”是人体发生机体障碍疾病和顽固疼痛的部位没有细菌感染，病理检查和组织切片找不到任何微生物侵害的迹象，从病理变化上来看是无菌性的，没有病源菌的炎症，因而抗生素治疗无效。有的人对某些物质过敏时也可引起炎症反应，如过敏性鼻炎、接触性皮炎、药物性皮炎、湿疹等。这些疾病虽然也有一个“炎”字，但不是因细菌感染引起的，如果使用抗菌消炎药物治疗，不但无效，有时反而因引起新的过敏反应而加重病情。治疗过敏性炎症应给以抗过敏药物，如息斯敏、扑尔敏或激素类抗过敏药物等。还有一些运动系统疾病，如关节炎、纤维组织炎、腱鞘炎、强直性脊柱炎等，这些炎症也不是病原微生物引起，不要用抗菌消炎药。
骨关节炎是一种常见的致残疾病，2006-2016年间全球伤残损失健康生命年百分比增长了31.5％，导致巨大的社会经济成本，对个体健康和卫生保健系统有显著影响。膝骨关节炎是骨关节炎最常见的亚型，主要影响老龄人群及肥胖人群，临床症状为膝关节疼痛、肿胀、僵硬和活动能力下降。膝骨关节炎的病理改变包含关节软骨退变、软骨下骨改变、骨赘形成和非细菌性滑膜炎，其发病机制复杂，起初认为与“磨损”这种机械应力有关，后发现微环境和遗传因素在疾病恶化过程中相互作用，最终导致关节软骨变性、关节内炎症伴滑膜炎和软骨下骨变化。软骨细胞产生和分泌的细胞外基质和成纤维细胞样滑膜细胞分泌的滑液是维持微环境的2种重要成分，但是软骨细胞仅占软骨体积的2％，所以膝骨关节炎发生时可能首先被来自滑膜或软骨下骨的炎症信号激活，从而改变细胞外基质合成和降解之间的平衡，导致关节软骨自我再生潜力有限。
目前关节炎治疗方法已经有多种形式。富血小板血浆(PRP)是新鲜全血离心后的自体产物，含有许多促进组织修复的生长因子(如血小板衍生生长因子AB、转化生长因子β1和血管内皮生长因子)。已有大量研究报道富血小板血浆对于年轻及影像学分级较低(Kellgren-lawrence分级2-3级)的膝骨关节炎患者能发挥疼痛缓解、功能提升及改善生活质量的作用。通过对80只胫骨近端骨折骨松质形成的观察研究表明，使用最高剂量PRP组显微CT骨体积/总体积显著增高，组织形态学上新骨面积和骨向内生长的深度也最高。
当然，除了PRP之外，还有多肽也能够用于关节炎的治疗。比如ZL200510040378.5高效抑制血管生成多肽及其制备方法和应用，还介绍了一种多肽，该多肽序列可以有效地结合于整合素亚型，并且该序列中含有新生血管抑制序列，能够新生血管形成。先前专利中只是对黑色素瘤做了研究，本发明针对该序列做了进一步研究，发现其对类风湿性关节炎有治疗作用，增加了其适用症，拓展了其社会价值和经济价值。
此外，MSCs已被许多研究报道具有免疫调节及抗炎作用，且仍然主要通过务分泌机制所分泌的EVs发挥作用。据报道脂肪来源的MSCs所分泌的EX(AD-MSCS-EX)对T细胞的增殖、分化和活化具有抑制作用。最近研究发现在IL-1β刺激的OA软骨细胞中，AD-MSCS-EVs减少了炎症介质(IL-6、TNF、前列腺素E2、NO等)的产生。IL-1B对抗炎细胞因子IL-10有抑制作用,而AD-MSCs-EVs能够抵消其抑制作用,并显示出对IL-10的表达有一定的增强作用。还有研究发现,MSCS-EVs可诱导IL-10和TGF-B1高表达,同时抑制IL-1B、IL-6、TNF-α、IL12/P40的表达。由此看来,MSCs-EVs具有一定的抗炎及免疫调节潜能。目前抗炎作用已在OA模型中得到证实，而免疫调节作用尚未在OA模型中得到证实。最近有研究表明,来自小鼠的MSCs-EVs可抑制CD8T淋巴细胞的增殖以及B淋巴细胞的增殖激活化，并且还增加了调节性T淋巴细胞群体,但对CD4 IFN-T淋巴细胞没有影响。因此，MSCs-EVs可能通过其抗炎及免疫调节潜能在OA治疗中发挥重要作用。
目前，有效治疗骨关节炎的组合物还不够多，特别是疗效好的具有自主知识产权的组合物类型也有待于进一步的丰富和完善。
发明内容
本发明一方面，提供了一种冻存PRP在制备治疗无菌性炎症疾病关节炎的药物中的用途。
更进一步的，所述的药物中还含有干细胞外泌体。
所述的干细胞外泌体是本领域常用的脂肪间充质干细胞外泌体。
所述的外泌体为采用本领域常用的外泌体制备方法制备获得的。
更进一步的，所述的药物中还含有具有鹿茸多肽活性肽，其氨基酸序列如SEQ IDNO：1所示。
更进一步的，所述的活性肽还可以被修饰或者保守性取代。
本发明的术语“保守取代”是指用具有相似结构和/或化学性质的不同氨基酸取代一个氨基酸。这种氨基酸取代通常可以基于残基的极性、电荷、溶解性、疏水性、亲水性和/或两亲性质的相似性而发生。在整个说明书中，使用了用于天然发生的氨基酸的常规单字母和三字母代码。此外，本文提及的氨基酸根据IUPAC-IUB的命名规则缩写如下。丙氨酸Ala、A精氨酸Arg、R；天冬酰胺Asn、N天冬氨酸Asp、D；半胱氨酸Cys、C谷氨酸Glu、E；谷氨酰胺Gln、Q甘氨酸Gly、G；组氨酸His、H异亮氨酸Ile、I；亮氨酸Leu、L赖氨酸Lys、K；甲硫氨酸Met、M苯丙氨酸Phe、F；脯氨酸Pro、P丝氨酸Ser、S；苏氨酸Thr、T色氨酸Trp、W；酪氨酸Tyr、Y缬氨酸Val、V；同时，任何氨基酸都可以描述为Xaa、X。进一步的，在具有侧链的带电荷氨基酸中，带正电荷(碱性)氨基酸包括精氨酸、赖氨酸和组氨酸，带负电荷(酸性)氨基酸包括谷氨酸和天冬氨酸；在具有侧链的不带电荷氨基酸中，非极性氨基酸包括甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、甲硫氨酸、苯丙氨酸、色氨酸和脯氨酸，极性或亲水氨基酸包括丝氨酸、苏氨酸、半胱氨酸、酪氨酸、天冬酰胺和谷氨酰胺。在非极性氨基酸中，芳香族氨基酸包括苯丙氨酸、色氨酸和酪氨酸。
进一步的，本发明的还提供一种治疗骨关节炎的药物组合物，所述药物组合物含有本发明的鹿茸多肽活性肽，其氨基酸序列如SEQ ID NO：1所示。
进一步的，所述的药物组合物还含有药学上可接受的载体。
本发明的药物组合物可以进一步含有崩解剂、粘合剂、增溶剂、流化剂、甜味剂、发泡剂、表面活性剂、防腐剂、pH调节剂、着色剂、香料。
进一步的，本发明的载体包括赋形剂。其中所述赋形剂选自：甘露醇、乳糖、山梨醇、木糖醇、葡萄糖、麦芽糖、甘氨酸、可溶性糊精、黄原胶、明胶、水解明胶、阿拉伯胶、果胶、瓜尔胶、桃胶、黄芪胶、金合欢胶、羧甲基纤维素钠、聚乙烯吡咯烷酮、卡波姆、羟丙基纤维素、羟丙基甲基纤维素、海藻酸盐、或其组合。上述制剂所用赋形剂可以为乳糖、蔗糖、甘露醇、葡萄糖、山梨醇、葡聚糖等糖的衍生物，淀粉、糊精等淀粉衍生物；微晶纤维素等纤维素衍生物；硅酸钙、硅铝酸镁等硅酸盐衍生物；磷酸氢钙等磷酸盐；海藻酸盐；碳酸钙等碳酸盐；硫酸钙等硫酸盐等无机类赋形剂。润滑剂可以为硬脂酸、硬脂酸钙、硬脂酸镁等硬脂酸金属盐；滑石粉；蜂蜡等蜡类；硼酸；己二酸；硫酸钠等硫酸盐；乙二醇；富马酸；月桂基硫酸钠等月桂基硫酸盐；硅酸水合物等硅酸类；淀粉衍生物。粘合剂可以为羟丙基纤维素、羟丙甲基纤维素、聚乙烯吡咯烷酮、聚乙二醇以及上述兼具粘合作用的物质。崩解剂可以为低取代羟丙基纤维素、羧甲基纤维素钙、羧甲基纤维素、交联羧甲基纤维素钠等纤维素衍生物；羧甲基淀粉，羧甲基淀粉钠，交联聚乙烯吡咯烷酮，纤维素类，上述淀粉衍生物。矫臭矫味剂可以为甜味剂、酸味剂、香料等。基质可以为可可豆脂、脂肪酸甘油酯等硬脂基料、甘油明胶基料、聚乙二醇类及它们的混合物。气雾剂载体可以为氢氟烷HFA类。粉雾剂载体可以为乳糖、甘露醇、葡萄糖、果糖、木糖醇、山梨醇，苏氨酸、天冬氨酸、谷氨酸、异亮氨酸、精氨酸、亮氨酸、甘氨酸等氨基酸。在实际操作中优选水溶性辅料。
其中所述药物组合物中还包括酸碱调节剂。在一个实施方案中，所述的酸碱调节剂选自氢氧化钠、氢氧化钾、磷酸二氢钠、磷酸氢二钠、磷酸二氢钾、磷酸氢二钾、盐酸、磷酸、硝酸、硫酸、或其组合。在一个实施方案中，所述的酸碱调节剂是盐酸溶液或者氢氧化钠溶液，例如1M盐酸溶液或者1M氢氧化钠溶液。
本发明的药物组合物进一步的还含有增塑剂。“增塑剂”的例子包括药物制剂通常使用的增塑剂。具体地说，例如，酯，例如柠檬酸三乙酯，中链甘油三酯，邻苯二甲酸二乙酯，邻苯二甲酸二丁酯，三醋酸甘油酯(三乙酰甘油)，丁基邻苯二甲酰基丁基乙醇酸酯，辛酸甘油基酯等等；醇，例如甘油，丙二醇，聚乙二醇，等等。对于增塑剂，优选化学式[HOCH2(CH2OCH2)nCH2OH(n＝2-870的整数)]的化合物，尤其优选聚乙二醇(PEG)。实际上用作增塑剂的PEG的例子包括聚乙二醇(Sanyo chemical industries,Ltd.生产)。尽管对PEG的平均分子量没有特别限制，但优选不小于200，更优选200-20000，这是由于小平均分子量可以提高吸湿性。当将PEG加入到用于膜包衣片剂等等的包衣试剂中时，优选，PEG的含量是包衣试剂的大约5-大约30wt％，尤其是大约10-25wt％，更优选大约10-大约20wt％。
进一步的，本发明的药物组合物可以是冻干形式。在制备本发明冻干粉针剂时，所配制的药液中，固形物含量是为1～20％(w/v)，优选1～15％(w/v)，再更优选1～10％。由于冻干粉针剂通常是在管状西林瓶中进行冷冻干燥得到，本领域技术人员理解这种产品在获得成品甚至在供医生使用之前，通常均呈现一个圆饼状，尽管该圆饼的体积理论上讲会比原有水溶液的体积少(稍有缩小)，然而通常这种缩小通常不会缩小到原水溶液体积50％，通常会在原水溶液体积的80-120％之间，更通常在原水溶液体积的90-100％之间，而从终产品西林瓶内可观察到原水溶液液面痕迹(主体饼状物因冻干缩小后残留在瓶壁上的液面痕迹，即便西林瓶中的冻干品因各种原因例如碰撞等原因而呈粉末状，通常仍然可以保留原有的液面痕迹)，据此痕迹亦可估计出该冷冻干燥组合物在冷冻干燥之前的水溶液体积。因此，虽然本发明提供的是一种基本无水的冷冻干燥粉针剂，然而根据该粉针剂仍然可以大致估计出其在配制时，至少在冷冻干燥开始之前的药液体积，根据该估计出的体积以及西林瓶中的干燥终产物的重量，亦可计算到在制备本发明冻干粉针剂时，所配制的药液中的固形物的含量。因此，根据本发明第一方面的冻干粉针剂，其在配制时的药液的固形物含量是为1～20％(w/v)，优选1～15％(w/v)，再更优选1～10％。
有益效果
本发明提供了一种采用冻存prp与干细胞外泌体治疗无菌性炎症疾病的用途，具体的，采用冻存prp与干细胞外泌体治疗关节炎。本发明的prp和外泌体能够较好的促进骨关节炎软骨细胞增殖。将prp和外泌体以及本发明筛选的活性肽一起使用能够有效的治疗骨关节炎模型小鼠的关节炎症状，能够显著的降低关节炎相关基因的表达量，具有较好的治疗效果。
附图说明
图1 prp和外泌体促进软骨细胞增殖效果图
图2活性肽促进软骨细胞增殖效果图
具体实施方式
通过下面的实施例可以对本发明进行进一步的描述，然而，本发明的范围并不限于下述实施例。本领域的专业人员能够理解，在不背离本发明的精神和范围的前提下，可以对本发明进行各种变化和修饰。本发明对试验中所使用到的材料以及试验方法进行一般性和/或具体的描述。虽然为实现本发明目的所使用的许多材料和操作方法是本领域公知的，但是本发明仍然在此作尽可能详细描述。以下实施例进一步说明本发明，而不是限制本发明。任何依据本发明构思所作出的仅仅为形式上的而非实质性的等效变换都应视为本发明的技术方案范畴。
实施例1PRP的制备及激活及冻干制备
收集小鼠全血,并将其以8:1(V/V)的比例添加到BAC001-ACD抗凝剂中，将样品轻轻搅拌以混合.样品进行两步离心:将20ml混合物在50ml离心管中以250g离心15min，将包含血小板的最上面两层转移到新的离心管中,并以1000g的速度离心15min。丢弃大部分上清液血浆和贫血小板血浆(PPP)层,并将沉淀的血小板重新悬浮在残留血浆中共获得1.8ml的PRP。
随后用10％CaCl2与前述PRP 1:9的比例迅速混匀，37℃放置1h后置于4℃冰箱过夜。次日见大量淡黄色澄清液体析出，即为激活态PRP。将试管置于离心机内，4℃，5000r/min离心30min。上清液即为激活态的PRP。
采用鼠TGF-β、IGF、PDGF、bFGF和VEGF检测试剂盒，检测激活态PRP与未激活的PRP相比，表达量均大幅得到提高，表明激活态PRP制备成功。
将激活态PRP进行冷冻干燥存储。具体的方法为：赋形剂是海藻糖和乙酸钠组成，二者浓度分别为2％和0.03％；其在与激活态PRP以体积比1：1混合后，所得混合液中海藻糖浓度为1％、乙酸钠浓度为0.015％；将混合液放入预降温至-46℃的冻干机进行真空干燥，保持真空度为＜15Pa，干燥12h后取出，即为冻干激活态PRP，室温密封干燥保存4周后，使用前加入该样本冻干前等体积灭菌注射用水充分混匀复水。
实施例2脂肪间充质干细胞外泌体的制备
取小鼠BMSCs(编号CSI031Mu01，武汉云克隆动物有限公司)在脂肪间充质干细胞无血清培养基(货号NC0103+NC0104.S，诺扬生物)培养60h，收集细胞培养上清液，将收集的上清液通过以下差速离心步骤收集BMSCs-Exo：300×g，10min；2000×g，10min；10000×g，30min；120000×g，90min。超速离心后，弃去上清液，沉淀即主要为BMSCs-Exo，用1mLPBS重悬，0.22μm滤膜过滤，-80℃保存。将20μLBMSCs-Exo悬液滴加在铜网上，室温1min后滴加20μL磷钨酸溶液，1min后吸去磷钨酸溶液，红外灯下烘烤10min，吸去多余液体，透射电镜下观察Exo的粒径几种在95-110nm，圆形囊泡双层膜结构。使用BCA法调整外泌体浓度为1mg/mL备用。
实施例3激活态PRP和外泌体活性验证
小鼠软骨细胞(购买自联迈生物，货号LM-003)培养在含10％FBS和1％青霉素/链霉素的DMEM/F12培养基中培养软骨细胞，培养条件为含5％CO2的37℃湿润的无菌细胞培养箱,1d换液1次，后续实验均采用对数生长期细胞。
按照CCK-8试剂盒说明检测软骨细胞的增殖。软骨细胞分为对照组(正常软骨细胞)、IL-1β组(模型组)、IL-1β+激活态PRP(50mg/L)组、IL-1β+激活态PRP(100mg/L)组、IL-1β+BMSCs-Exo(50mg/L)组、IL-1β+激活态PRP(50mg/L)+BMSCs-Exo(50mg/L)组进行相应处理。在120h时,向每个孔中加入10μl CCK-8溶液和100μl新鲜培养基,并在37℃下孵育4h.用酶标仪在450nm的波长下检测光密度值。软骨细胞的存活/增殖表示为测试孔的光密度值减去空白孔的光密度值。结果如图1所示。
从图1结果可以看出，IL-1β抑制了细胞增殖(P＜0.05，与对照组相比)，而激活态PRP和BMSCs-Exo都能够有效促进骨关节炎软骨细胞增殖,而且激活态PRP和BMSCs-Exo联合使用，能够更有效的促进软骨细胞增殖(P＜0.05，相对于模型组)。
实施例4鹿茸多肽高活性肽筛选和鉴定
梅花鹿鹿茸2kg,剁成小块(1cm2左右)，用4℃蒸馏水冲洗至无血色，粉碎，胶体磨匀浆，不断添加预冷的匀浆液(pH3.5 HAc溶液)，9000r/min，离心20min，取上清，加入95％乙醇使其终浓度达到65％，4℃放置并搅拌30min，随后9000r/min离心20min,取上清，55℃真空旋转蒸发,回收乙醇,冻干得到鹿茸粗提物，-20℃保存。
将鹿茸提取物采用胰蛋白酶(4×104U/g)按照底物浓度5％，酶底比为10％，温度为40摄氏度，pH为9的条件下酶解4h。煮沸10min灭酶，冷却后调至pH7。在8000rpm下离心15min去沉淀，通过超滤，收集分子量小玉5Kda的组分，然后采用SephadexG-25(1.6cm×60cm)对肽液进行分离，加样量为1mL，以水为洗脱剂，流速为1.5mL/min。在280nm处检测吸光度，收集各洗脱峰，进行真空浓缩干燥，检测各峰对软骨细胞增殖效果较好的2号峰，采用Superdex75凝胶过滤层析进行再分离，色谱条件如下：玻璃柱：柱长*直径(1.6cm×80cm)流动相：纯水(微孔滤膜过滤)流速：3mL/min温度：4℃检测波长：280nm上样体积3.0mL，收集活性较好的2-II号峰进行HPLC高效液相色谱层析，色谱柱：Agilent公司300SB-C18；规格：4.6mmX250mm；流速：0.5mL/min；温度：20℃；检测波长：214nm,230nm280nm；流动相A：0.1％三氟乙酸的水溶液；流动相B：0.1％三氟乙酸的乙腈溶液，经C18反相层析柱分离纯化后共得到4个组分，体外软骨细胞增殖活性鉴定活性组分主要集中在峰2部分。将峰2部分委托百泰派克生物科技进行测序，鉴定氨基酸序列如SEQ ID NO：1所示，人工合成所述多肽，HPLC鉴定纯度为99％以上。
小鼠软骨细胞(购买自联迈生物，货号LM-003)培养在含10％FBS和1％青霉素/链霉素的DMEM/F12培养基中培养软骨细胞，培养条件为含5％CO2的37℃湿润的无菌细胞培养箱,1d换液1次，后续实验均采用对数生长期细胞。
按照CCK-8试剂盒说明检测软骨细胞的增殖。软骨细胞分为对照组、IL-1β组(模型组)、IL-1β+活性肽(10mg/L)组、IL-1β+活性肽(50mg/L)组、IL-1β+活性肽(100mg/L)组、IL-1β+活性肽(200mg/L)组进行相应处理。在120h时,向每个孔中加入10μl CCK-8溶液和100μl新鲜培养基,并在37℃下孵育4h，用酶标仪在450nm的波长下检测光密度值。软骨细胞的存活/增殖表示为测试孔的光密度值减去空白孔的光密度值。结果如图2所示。
从图2可以看出，本发明分离得到的活性肽具有剂量依赖性的促进软骨细胞增殖的效果(与模型组相比，P＜0.05)。
实施例5大鼠骨关节炎模型的构建及治疗
实验前适应性喂养7d，随后从SPF级SD雄性大鼠中随机抽取10只作为空白组，其余大鼠建造膝骨关节炎模型，造模过程无大鼠死亡。造模方法：麻醉药物选择10％的水合氯醛溶液，抓取大鼠以3mL/kg剂量对其腹腔注射。待大鼠充分麻醉后，将大鼠膝关节待注射处毛发剃净，棉签蘸取体积分数75％的乙醇消毒，然后屈曲大鼠膝关节至45°左右，以髌韧带胫骨附着点外上方约1mm处为进针点，然后抽取4％木瓜蛋白酶0.2mL+0.03mol/L的L-半胱氨酸混合溶液，经皮肤刺入有落空感即表明针头到达关节腔内，随即进行注射，注射完毕退出针头后，使用棉签压迫针口以防出血，另一膝关节采用同样方法完成木瓜蛋白酶注射，所有注射完成后给予20万U青霉素钠肌注以防大鼠感染。每隔3d(即第1，4，7天)进行1次上述造模操作，共3次。
把所有膝骨关节炎模型大鼠随机分为模型组、低剂量多肽组、高剂量多肽组、高剂量多肽+激活态PRP+BMSCs-Exo组、阳性对照组，每组10只大鼠。造模后所有大鼠跑步1周，然后每组随机抽取1只大鼠处死，取膝关节做组织切片，显微镜下观察关节软骨表面粗糙，个别可见裂隙，组织结构紊乱，软骨细胞弥漫增多，参照本领域常见的改良版Mankin评分标准(参见Acoustic stifness and changein plug cartilage over time after autologousosteochondral grafting:correlation between ultrasound signal intensity andhistological score in a rabbit model.)，确定造模成功。
其余大鼠确定造模成功当天即开始膝关节显微注射。空白组不做任何处理；模型组每天予以体质量相关剂量生理盐水注射；低剂量多肽组予10mg/kg多肽微量注射；高剂量多肽组予50mg/kg多肽微量注射；高剂量多肽+激活态PRP+BMSCs-Exo组予50mg/kg多肽微量注射，间隔2h后微量注射激活态PRP 10mg/kg，再加个2h后微量注射BMSCs-Exo 10mg/kg；阳性对照组予18mg/kg的塞来昔布胶囊水溶液灌胃。所有干预每日1次，共给药4周。
末次干预结束后禁食不禁水24h，使用10％水合氯醛溶液麻醉所有大鼠，对其进行腹主动脉采血。采血完毕后，使用颈椎脱臼法处死大鼠，屈曲右膝关节，使用剪刀剪开膝关节处皮肤，手术刀沿髌骨内侧从上至下打开关节囊并去除髌骨，剪刀等小心剥离胫骨平台周围韧带等软组织，使软骨暴露，使用骨剪轻轻取下右膝胫骨平台表面软骨置于2mL冻存管中，-80℃保存备用；分离左膝关节软组织并暴露胫骨平台软骨后，咬骨钳于胫骨约1/2处咬断胫骨，附带关节软骨的胫骨整个置于装有40g/L多聚甲醛的离心管中固定，以便随后石蜡标本的制作。针对大鼠软骨番红固绿染色及Mankin评分；结果如表1所示。
表1各组大鼠Mankin评分
注：a与空白组相比，P<0.05；b与模型组相比；P<0.05。
从表1可以看出，干预4周后与空白组相比，其余各组软骨Mankin评分均较高(P<0.05)；与模型组相比，各治疗组评分均较低(P<0.05)，而多肽联合外泌体以及激活态PRP具有相对于阳性对照组更好的治疗效果(P<0.05)，也比单独治疗的效果要好。
此外，荧光定量PCR检测软骨中Col2α1mRNA表达分别取50mg左右各组大鼠的软骨组织，使用Trizol法提取总RNA，洗涤后无RNase水溶解RNA，根据反转录试剂盒说明书进行反转录操作得到cDNA，将上述cDNA模板与缓冲液、dNTP、引物、TaqDNA聚合酶等离心混匀于EP管构建反应体系，于PCR仪器上进行扩增。采用2-ΔΔCt法计算Col2α1mRNA的相对表达量。所述的引物序列如下：Col2α1Forward：5’-CATCGAGTACCGATCACAGAAG-3’；Reverse：5’-GCCCTATGTCCACACCAAAT-3’；GAPDHForward：5’-GCAAGGATACTGAGAGCAAGAG-3’；Reverse：5’-GGATGGAATTGTGAGGGAGATG-3’。
表2各组大鼠关节软骨Col2α1mRNA表达结果
#与空白组相比，P<0.05；！与模型组相比，P<0.05
从表2可以看出，模型组的Col2α1mRNA表达相较空白组显著上调(P<0.05)，而各治疗组与模型组相比，表达量则显著降低，有显著性意义(P<0.05)。由于Col2aα1是膝关节软骨中间接反映软骨修复作用，模型组的Col2α1mRNA表达水平高是由于软骨的损伤刺激了机体的代偿作用导致Col2α1mRNA的表达增加，而各治疗组能够降低Col2α1mRNA表达水平，进而对早期膝骨关节炎大鼠的软骨具有一定的保护作用。
最后应说明的是：以上各实施例仅用以说明本发明的技术方案，而非对其限制；尽管参照前述各实施例对本发明进行了详细的说明，但本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分或者全部技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (5)
1.一种能够促进软骨细胞增殖的活性肽，所述的活性肽的氨基酸序列如SEQ ID NO：1所示。
2.如权利要求1所述的活性肽在制备促进软骨细胞增殖的药物中的用途。
3.一种用于治疗骨关节炎的药物组合物，其特征在于：由冻存的富血小板血浆prp、脂肪间充质干细胞外泌体以及活性肽组成，所述的活性肽的氨基酸序列如SEQ ID NO：1所示；所述的prp是激活态的prp冻干粉。
4.一种用于治疗骨关节炎的药物组合物，其特征在于：由冻存的富血小板血浆prp、脂肪间充质干细胞外泌体、活性肽以及药学上可接受的载体组成，所述的活性肽的氨基酸序列如SEQ ID NO：1所示；所述的prp是激活态的prp冻干粉。
5.冻存的富血小板血浆prp、脂肪间充质干细胞外泌体以及活性肽在制备治疗骨关节炎的药物组合物中的用途，所述的活性肽的氨基酸序列如SEQ ID NO：1所示；所述的prp是激活态的prp冻干粉。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410230477.2A CN118027175B (zh) | 2024-02-29 | 2024-02-29 | 冻存prp与干细胞外泌体治疗无菌性炎症疾病 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410230477.2A CN118027175B (zh) | 2024-02-29 | 2024-02-29 | 冻存prp与干细胞外泌体治疗无菌性炎症疾病 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118027175A CN118027175A (zh) | 2024-05-14 |
| CN118027175B true CN118027175B (zh) | 2024-07-26 |
Family
ID=90987447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410230477.2A Active CN118027175B (zh) | 2024-02-29 | 2024-02-29 | 冻存prp与干细胞外泌体治疗无菌性炎症疾病 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118027175B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118812659A (zh) * | 2024-07-02 | 2024-10-22 | 北京川晋生物科技有限公司 | 一种包含prp的组合物及其在治疗炎症中的用途 |
| CN119192293B (zh) * | 2024-09-24 | 2025-06-20 | 诺瓦赛尔生物科技(南京)有限公司 | 包含冻存prp的组合物在治疗妇科疾病中的用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114031672A (zh) * | 2021-11-17 | 2022-02-11 | 广州领晟医疗科技有限公司 | 一种多肽及其在制备软骨修复和/或骨关节炎药物中的应用 |
| CN115068616A (zh) * | 2022-06-16 | 2022-09-20 | 广州惠善医疗技术有限公司 | 间充质干细胞来源外泌体联合非甾体抗炎药在制备预防或治疗骨关节疾病药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1314705C (zh) * | 2005-06-03 | 2007-05-09 | 中国药科大学 | 高效抑制血管生成多肽及其制备方法和应用 |
| WO2022191341A1 (ko) * | 2021-03-08 | 2022-09-15 | 주식회사 엑소스템텍 | 줄기세포로부터 유래한 엑소좀을 포함하는 관절염 완화 또는 치료용 약학적 조성물 |
-
2024
- 2024-02-29 CN CN202410230477.2A patent/CN118027175B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114031672A (zh) * | 2021-11-17 | 2022-02-11 | 广州领晟医疗科技有限公司 | 一种多肽及其在制备软骨修复和/或骨关节炎药物中的应用 |
| CN115068616A (zh) * | 2022-06-16 | 2022-09-20 | 广州惠善医疗技术有限公司 | 间充质干细胞来源外泌体联合非甾体抗炎药在制备预防或治疗骨关节疾病药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118027175A (zh) | 2024-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118027175B (zh) | 冻存prp与干细胞外泌体治疗无菌性炎症疾病 | |
| CN112601533B (zh) | 将含有源自干细胞的外泌体的培养液作为有效成分包含的关节炎预防或治疗用组合物 | |
| AU2011272137B2 (en) | Novel peptide and use thereof | |
| JP6577038B2 (ja) | 軟骨細胞に分化されている幹細胞由来のエキソソームを含む軟骨細胞への分化誘導または軟骨組織再生用組成物 | |
| KR101629151B1 (ko) | 줄기세포 유래 엑소좀을 포함하는 지방세포 분화유도 및 지방조직 재생용 조성물 | |
| JPS6391325A (ja) | 顆粒球コロニ−刺激因子を含有する徐放性製剤 | |
| FR2553099A1 (fr) | Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant | |
| WO2023035632A1 (zh) | 一种活性肽及其相关用途 | |
| US20230399353A1 (en) | Amino acid derivative of glucosamine stimulating extracellular matrix synthesis and pharmaceutical composition comprising the same | |
| CA3117723A1 (en) | Methods of cellular reprogramming | |
| CN109836487B (zh) | 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用 | |
| CN104918629B (zh) | Sp肽或其衍生物在制备降低il‑13水平的药物中的应用 | |
| RU2292212C1 (ru) | Кондиционная среда, обладающая лечебным эффектом | |
| CN113244376A (zh) | 一种提高免疫促进伤口愈合的药物及其制备方法 | |
| KR20240086947A (ko) | 연골 재생용 펩타이드 및 이의 용도 | |
| KR20240086946A (ko) | 연골 재생용 펩타이드 및 이의 용도 | |
| CN113171441A (zh) | 提高免疫促进伤口愈合的药物组合物及其制备方法 | |
| KR20240087877A (ko) | 연골 재생용 펩타이드 및 이의 용도 | |
| KR20240086944A (ko) | 연골 재생용 펩타이드 및 이의 용도 | |
| Hung | Collagen binding peptide for mesenchymal stem cell regeneration medicine | |
| KR20240086941A (ko) | 연골 재생용 펩타이드 및 이의 용도 | |
| CN120361249A (zh) | 一种甲钴胺纳米功能化的胶原多糖海绵及其应用 | |
| KR20240086939A (ko) | 연골 재생용 펩타이드 및 이의 용도 | |
| WO2021116705A1 (en) | Collagen production | |
| CN120418270A (zh) | 用于软骨再生的肽及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240703 Address after: 050000 Tianshan Avenue, Shijiazhuang High-tech Zone, Hebei Province, No. 585 Rizhongtian Innovation Science Park Building Applicant after: HEBEI LIFEORIGIN BIOTECHNOLOGY Co.,Ltd. Country or region after: China Address before: No. 144, Office Building, Cultural Activity Center, Zhangshanying Town, Yanqing District, Beijing, 100000 Applicant before: Beijing Wangjiang Biotechnology Co.,Ltd. Country or region before: China |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |